New validated RP-HPLC method for the estimation of Carvedilol in pharmaceutical formulation

International Journal of Pharmacy and Pharmaceutical Sciences

Volumn 4, Issue 2, 2012, Pages 353-358

  Basaveswara Rao, M V ^a   Nagendrakumar, A V D ^b   Yedukondalu, M ^c   Raman, B V ^d  

^a KRISHNA UNIVERSITY   (India)

^b JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY   (India)

^c GITAM UNIVERSITY   (India)

^d K L UNIVERSITY   (India)

Author keywords

Carvedilol; Precise; Recovery; RP HPLC; UV detection

Indexed keywords

ACETONITRILE; CARVEDILOL; METHANOL;

ACCURACY; ARTICLE; BULK FORMULATION; CONTROLLED STUDY; DRUG FORMULATION; DRUG STRUCTURE; ELUTION; ENVIRONMENTAL TEMPERATURE; FLOW RATE; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SENSITIVITY AND SPECIFICITY; SPECTRAL SENSITIVITY; TABLET FORMULATION; ULTRAVIOLET RADIATION; VALIDATION STUDY;

EID: 84860012532     PISSN: None     EISSN: 09751491     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Arozal W, Sari FR, Watanabe K, Arumugam S, Veeraveedu PT, Ma M, Thandavarayan RA, Sukumaran V, Lakshmanan AP, Kobayashi Y, Mito S, Soetikno V, Suzuki K. Carvedilol-Afforded Protection against Daunorubicin-Induced Cardiomyopathic Rats In Vivo: Effects on Cardiac Fibrosis and Hypertrophy. ISRN Pharmacol, 2011: 430-549.
2. Othman AA, Tenero DM, Boyle DA, Eddington ND, Fossler MJ. Population pharmacokinetics of S (-)-Carvedilol in healthy volunteers after administration of the immediate-release (IR) and the new controlled-release (CR) dosage forms of the racemate. AAPSJ, 2007; 9 (2): E208-18.
3. Hashemzadeh M, Movahed MR, Russu WA, Soroush L, Hill DN. Novel design and synthesis of modified structure of carvedilol. Recent Pat Cardiovasc Drug Discov. 2011; 6(3):175-9.
4. Stafylas PC, Sarafidis PA. Carvedilol in hypertension treatment. Vasc Health Risk Manag, 2008; 4 (1): 23-30.
5. Vanderhoff BT, Ruppel HM, Amsterdam PB. Carvedilol: The new role of beta blockers in congestive heart failure. Am FAM Physician, 1998; 58(7):1627-34.
6. Suddhasattya D, Dhiraj Kumar SA, Sreenivas D, Sandeep AC. Analytical method development & validation of carvedilol by HPLC in bulk and dosage form. Journal of Pharmacy Research, 2010; 3(12): 3075-3077.
7. Pattana S, Somsak K, Sakawrat T. Development of Carvedilol assay in tablet dosage form usingHPLC with fluorescence detection. Maejo Int J Sci Technol, 2010; 4(1): 8-19.
8. Patel LJ, Suhagia BN, Shah PB, Shah RR. RP-HPLC and HPTLC methods for the estimation of Carvedilol in bulk drug and pharmaceutical formulations. Ind J pharma sci, 2006; 68(6): 790-793.
9. Eric Y, Sherry W, John K, Matthew JC. Stereoselective analysis of Carvedilol in human plasma using HPLC/MS/MS after chiral derivatization. J Pharm Biom Anal, 2004; 36(3- 15): 609-615.
10. Galanopoulou O, Rozou S, Antoniadou-Vyza E. HPLC analysis, isolation and identification of a new degradation product in Carvedilol tablets. J Pharm Biom Anal, 2008; 48(1- 10): 70-77.
11. Peccinini RG, Ximenes VF, Cesarino EJ, Lanchote VL. Stereoselective analysis of Carvedilol in human plasma and urine using HPLC after chiral derivatization. Biopharm Drug Dispos, 2008; 29(5): 280-8.
12. Ptacek P, Macek J, Klíma J. Liquid Chromatographic Determination of Carvedilol in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci, 2003; 789 (2): 405-410.
13. Saito M, Kawana J, Ohno T, Kaneko M, Mihara K, Hanada K, Sugita R, Okada N, Oosato S, Nagayama M, Sumiyoshi T, Ogata H. Enantioselective and highly sensitive determination of Carvedilol in human plasma and whole blood after administration of the racemate using normal-phase highperformance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci, 2006; 843(1): 73-77.
14. Soo-Hwan K, Sang Hun L, Hye Jung L. Rapid and Sensitive Carvedilol Assay in Human Plasma Using a High-Performance Liquid Chromatography with Mass/Mass Spectrometer Detection Employed for a Bioequivalence Study. Am J Analy Chem, 2010; 1: 135-14.
15. Gannu R, Yamsani VV, Rao YM. New RP-HPLC method with UVdetection for the determination of Carvedilol in human Serum. J Liq Chromatogr Relat Technol, 2007; 30(12): 1677-1685.
16. Q2A: Text on Validation of Analytical Procedures. In International Conference on Harmonization, Federal Register 1995; 60(40): 11260-11262.
17. Q2B: Validation of Analytical Procedures: Methodology, Availability. In International Conference on Harmonization. Federal Register 1997; 62(96): 27463-27467.
18. FDA: Analytical Procedures and Methods Validation: Chemistry, Manufacturing and Controls Documentation; Availability. Federal Register (Notices), 2000; 65(169): 52776-52777.
19. Vijay Kumar B, Pratap Kumar K, Suresh K, Saheena A, Srikanth P, Suneetha Y. Development and validation of RP-HPLC method for determination of Raloxifene Hydrochloride from pharmaceutical preparation. J Chem Pharm Res, 2011; 3(3):784-791. [www.fda.gov/cder/guidance/cmc3.pdf].
20. USP 25-NF 20, Validation of Compendial Methods Section (1225) (United States Pharmacopeal Convention, Rockville, Maryland, USA, 2002) p 2256.
21. Shabir GA. Validation of HPLC Chromatography Methods for Pharmaceutical Analysis. Understanding the Differences and Similarities between Validation Requirements of FDA, the US Pharmacopeia and the ICH. J Chromatogr A, 2003; 987(1-2): 57-66.
22. Wood CE. Medicare Program; Changes to the Hospital Outpatient Prospective. Med J Aust, 1996; 165: 510-514.
23. International Conference on Harmonization (ICH) of Technical Requirements for the Registration of Pharmaceuticals for Human Use, Validation of analytical procedures: definitions and terminology, Geneva (1996) adopted by Ravichandran V, Shalini S, Sundram KM, Harish R. Validation of analytical methods - strategies & importance. Int J Pharmacy and Pharm Sci, 2003; 2(3): 18-22.
24. U.S. FDA, Title 21 of the U.S. Code of Federal Regulations: 21 CFR 211-Current good manufacturing practice for finished pharmaceuticals. [http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm].
25. U.S. FDA - Guidance for Industry (draft) Analytical Procedures and Methods Validation: Chemistry, Manufacturing, and Controls and Documentation, 2000 [http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm122858.pdf].
26. ISO/IEC 17025, General requirements for the competence of testing and calibration laboratories, 2005 [http://www.a2la.org/requirements/req17025.pdf].
27. International Conference on Harmonization (ICH) of Technical Requirements for the Registration of Pharmaceuticals for Human Use, Validation of analytical procedures: Methodology, adopted in 1996, Geneva adopted by Peinado A, Hammond J, Scott A. Development, validation and transfer of a near infrared method to determine in-line the end point of a fluidised drying process for commercial production batches of an approved oral solid dose pharmaceutical product. J Pharm Biomed Anal. 2011, 5; 54(1):13-20.
28. U.S. EPA, Guidance for methods development and methods validation for the Resource Conservation and Recovery Act (RCRA) Program, Washington, D.C. (1995). [http://www.epa.gov/sw-846/pdfs/methdev.pdf].
29. General Chapter 1225, Validation of compendial methods, United States Pharmacopeia 30, National Formulary 25, Rockville, Md., USA, The United States Pharmacopeial Convention, Inc., (2007) adopted by Ronnie DP, JoAnn S. Medicare Part D: Selected Issues for Plan Sponsors, Pharmacists, and Beneficiaries in 2008. J Manag Care Pharm, 2008; 14(1): 50-60.
30. U.S. FDA - Guidance for Industry, Bioanalytical Method Validation adopted by Shen G, Hong JL, Kong AN. Development and validation of an HPLC method for the determination of dibenzoylmethane in rat plasma and its application to the pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci, 2007; 852(1-2): 56-61.
31. Hokanson GC. A life cycle approach to the validation of analytical methods during pharmaceutical product development, Part I: The initial validation process. Pharm. Tech. 1994, pp. 118-130.